COX-2 inhibitors and hypercoagulability.
Farkouh
Michael E
ME
New York University School of Medicine, New York, NY 10016, USA.
D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use*; D018579:Patient Selection; D012307:Risk Factors; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use*; D019851:Thrombophilia / Q000139:chemically induced*
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib